General Information of Drug (ID: DMC21G0)

Drug Name
CSL311 Drug Info
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMC21G0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tagraxofusp DM9HQ5U Acute myeloid leukaemia 2A60 Approved [3]
CD123/CLL1 CAR-T Cells DM45Z3P Acute myeloid leukaemia 2A60 Phase 2/3 [4]
Talacotuzumab DMARVFG Acute myeloid leukaemia 2A60 Phase 2 [5]
MB-102 DMLPNVS Acute kidney injury GB60 Phase 2 [5]
Flotetuzumab DMVR6OM Acute biphenotypic leukaemia 2B33.4 Phase 2 [5]
4SCAR19 and 4SCAR123 DMYPQT4 B-cell lymphoma 2A86 Phase 1/2 [6]
SAR440234 DM6M8O4 Acute myeloid leukaemia 2A60 Phase 1/2 [7]
CD123-specific gene-engineered T cells DMHOWU5 Acute myeloid leukaemia 2A60 Phase 1/2 [8]
CART-123 cells DM0MCTJ Acute myeloid leukaemia 2A60 Phase 1/2 [9]
CART-123 cells DM0MCTJ Acute myeloid leukaemia 2A60 Phase 1/2 [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Benralizumab DM7P1J4 Asthma CA23 Approved [11]
YM90709 DML5DU0 Discovery agent N.A. Investigative [12]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 3 receptor alpha (IL3RA) TTENHJ0 IL3RA_HUMAN Not Available [2]
Interleukin 5 receptor alpha (IL5RA) TTXH9AD IL5RA_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT04082754) A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Subjects With Mild-to-moderate Asthma and in Healthy Volunteers. U.S.National Institutes of Health.
2 Anti-beta(c) mAb CSL311 inhibits human nasal polyp pathophysiology in a humanized mouse xenograft model. Allergy. 2020 Feb;75(2):475-478.
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
7 Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
8 ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
9 ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
10 ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML
11 Benralizumab--a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8.
12 Characterization of YM-90709 as a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor. Int Immunopharmacol. 2002 Nov;2(12):1693-702.